Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals. Pixantrone was specifically designed to have a higher affinity and avidity for the topisomerase II enzyme, which is the common target for this class of anti-cancer agents, while reducing oxygen-free radicals and preventing the formation of toxic drug metal complexes, which are the primary culprit that leads to dose-related irreversible heart damage associated with standard anthracyclines.

"This study adds to the growing scientific evidence which is central to the mechanistic basis for the relatively low incidence of cardiac events observed in our pixantrone clinical trials compared to the expected incidence of events had other anthracyclines been used. The ability to reintroduce an effective anthracycline like agent to patients who are no longer eligible to receive further standard anthracycline therapy due to potential irreversible heart damage addresses a major and growing unmet medical need," Jack Singer, M.D., Chief Medical Officer of Cell Therapeutics, Inc.

About the Study

To validate the proposed mechanisms underlying the observed differences in cardiotoxicity, researchers used established spectrophotometric techniques to quantify iron and drug interactions that are thought to be mechanistic for chronic doxorubicin cardiotoxicity. When adding increasing amounts of iron to drug solutions, they observed that doxorubicin and mitoxantrone underwent changes in visible range absorbance patterns, which is charact
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... Texas , July 31, 2014 Vermillion, Inc. ... and women,s health, will hold a conference call on Thursday, ... results for the second quarter ended June 30, 2014. Financial ... the call. Vermillion,s Chairman, President and CEO ... question and answer period. Date: Thursday, August 14, ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... HOFFMAN ESTATES, Ill., Jan. 24, 2012 Life Spine, a ... for the surgical treatment of spinal disorders, announced record revenues ... introductions in 2011. The record revenue reflects ... 2011. "This has been an outstanding year for Life Spine. ...
... 2012  LoneStar Heart Inc., based here, today announced that ... Maciejewski to the company,s board of directors. The new ... for LoneStar Heart; Frank Ahmann, the company,s president and ... of Vessix Vascular, Inc.; and Eric N. Olson, Ph.D., ...
Cached Medicine Technology:LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 2LoneStar Heart Inc. Names Andrew J. Coats, M.D., and Mark Maciejewski to Its Board of Directors 3
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... FL (PRWEB) July 31, 2014 Zensah®, ... released their innovative compression elbow sleeve , designed ... elbow pain, in two new bright colors for summer. ... pink and blue. Made of innovative proprietary Zensah® fabric, ... wicking and odor-preventing fabric. It features a no-slip cuff ...
(Date:7/31/2014)... 31, 2014 To further educate the ... provide the following safety information regarding leaving children in ... can have deadly consequences. Because a child’s body can ... of adults, leaving children alone in a hot vehicle ... even death. , Statistics of Children Left Alone in ...
(Date:7/31/2014)... 2014 Most mommy blogs are simple ... purpose is to attract all mothers from all walks ... particular group; whether its high fashion or child rearing. ... everything on the Internet was so segmented. “I found ... particular topic and then search Google to get information ...
(Date:7/31/2014)... A chance meeting at last April’s ... country artist/writer-producer Jimmy Robbins to Etymotic Research and ... an innovator in hearing wellness solutions, and maker ... 2012, Etymotic’s Music•PRO® Electronic Earplugs have revolutionized hearing ... and restoring natural hearing when hearing is not ...
Breaking Medicine News(10 mins):Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2Health News:Country Star Jimmy Robbins Now Using Etymotic’s MusicPRO Electronic Earplugs 2
... ultrasound and specially modified contrast agents may allow researchers ... to research published in the March issue of The ... The technique enables researchers to visualize tumor activity at ... be helpful for the early detection of disease," said ...
... If the behavior of the seasonal form of the ... are good that most strains of the pandemic H1N1 flu ... for use against it. Researchers at Ohio State University ... virus, which first infected humans during the 1918 pandemic. It ...
... ... beef sold at checkout could help save lives when E. coli outbreaks happen because ... identify the products that are making people sick in order to bring outbreaks under ... ...
... ... has launched an improved web viewer for its flagship Evercore® – Clinical Enterprise Suite ... of the size of the facility. , ... Milwaukee, WI (PRWEB) March 1, 2010 -- TeraMedica Healthcare Technology, ...
... ... in Pharma, Health and Wellness. , ... Philadelphia, PA (PRWEB) March 1, 2010 -- Acknowledging more than 13 ... for specialization, Razorfish has launched Razorfish Health , a dedicated health and wellness ...
... ... ... ... ...
Cached Medicine News:Health News:The proof's in the bubbles 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 2Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 3Health News:Pandemic flu, like seasonal H1N1, shows signs of resisting Tamiflu 4Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 2Health News:Food Safety Attorney Fred Pritzker Calls on Food Retailers to Keep Precise Beef Handling Records 3Health News:TeraMedica Unveils Improved Univision, Now Offering a Multi-Layer Enterprise Viewing Platform 2Health News:Razorfish Launches Independent Dedicated Health Brand 2Health News:Razorfish Launches Independent Dedicated Health Brand 3Health News:Razorfish Launches Independent Dedicated Health Brand 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 2Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 3Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 4Health News:California to Examine Health Impacts of Landmark Cap-and-Trade Program 5
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... are constructed of a patented ... polyvinyl acetal sponge. Each device ... to both surgeon and patient, ... firm enough to gently manipulate ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
Medicine Products: